Knight Therapeutics NIKTIMVO® Receives Brazilian Regulatory Approval
Knight Therapeutics Inc. has received expedited regulatory approval under ANVISA’s rare disease pathway for NIKTIMVO® (axatilimab) for the treatment of chronic graft-versus-host disease.